Format

Send to

Choose Destination
Can J Neurol Sci. 2016 Sep;43(5):626-34. doi: 10.1017/cjn.2016.274.

Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation.

Author information

1
1Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease,Toronto Western Hospital,and Division of Neurology,University Health Network,University of Toronto,Toronto,Ontario,Canada.
2
3Pacific Parkinson's Research Centre,Djavad Mowafaghian Centre for Brain Health,University of British Columbia,Vancouver,British Columbia,Canada.
3
4Clinical Neurological Sciences,Movement Disorders Centre,Lawson Health Research Institute and Western University,London,Ontario,Canada.
4
5Department of Psychiatry,University of Toronto,Toronto,Ontario,Canada.
5
6Division of Neurology,Toronto Western Hospital,University Health Network,Toronto,Ontario,Canada.
6
8Department of Medicine and Surgery,Centre for Neurodegenerative Diseases,University of Salerno,Salerno,Italy.
7
9Division of Neurosurgery,University of British Columbia,Vancouver,British Columbia,Canada.

Abstract

In this review, we have gathered all the available evidence to guide medication management after deep brain stimulation (DBS) in Parkinson's disease (PD). Surprisingly, we found that almost no study addressed drug-based management in the postoperative period. Dopaminergic medications are usually reduced, but whether the levodopa or dopamine agonist is to be reduced is left to the personal preference of the treating physician. We have summarized the pros and cons of both approaches. No study on the management of cognitive problems after DBS has been done, and only a few studies have explored the pharmacological management of such DBS-resistant symptoms as voice (amantadine), balance (donepezil) or gait disorders (amantadine, methylphenidate). As for the psychiatric problems so frequently reported in PD patients, researchers have directed their attention to the complex interplay between stimulation and reduction of dopaminergic drugs only recently. In conclusion, studies addressing medical management following DBS are still needed and will certainly contribute to the ultimate success of DBS procedures.

KEYWORDS:

Deep brain stimulation; Globus pallidus internus; Medication; Parkinson’s disease; Subthalamic nucleus

PMID:
27670207
DOI:
10.1017/cjn.2016.274
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center